Plazomicin: A Next-Generation Aminoglycoside.

Area of Science:

• Pharmacology and Infectious Diseases
• Antimicrobial Resistance
• Clinical Trials

Background:

• Aminoglycoside antibiotics target the bacterial 30S ribosomal subunit, inhibiting protein synthesis.
• Emergence of multidrug-resistant gram-negative bacteria necessitates novel therapeutic agents.
• Plazomicin demonstrates broad-spectrum activity against challenging pathogens like carbapenem-resistant Enterobacteriaceae.

Purpose of the Study:

• To evaluate the efficacy and safety of plazomicin in treating complicated urinary tract infections (cUTIs).
• To assess plazomicin's effectiveness in infections caused by carbapenem-resistant Enterobacteriaceae.
• To establish plazomicin as a viable treatment option for adults with limited or no alternative therapies.

Main Methods:

• Phase III clinical trials comparing plazomicin to meropenem for cUTIs.
• Evaluation of microbiologically modified intent-to-treat composite cure rates.
• Assessment of all-cause mortality and disease-related complications in carbapenem-resistant Enterobacteriaceae infections.

Main Results:

• Plazomicin demonstrated non-inferiority to meropenem in treating cUTIs.
• Plazomicin showed a lower mortality rate compared to colistin in carbapenem-resistant Enterobacteriaceae infections.
• Common adverse reactions include decreased renal function, diarrhea, hypertension, and gastrointestinal issues.

Conclusions:

• Plazomicin is an effective and safe alternative for treating cUTIs, especially those caused by multidrug-resistant gram-negative bacteria.
• The drug is indicated for adults with limited or no alternative treatment options.
• Dosage adjustments and therapeutic drug monitoring are crucial for patients with renal impairment.